343 related articles for article (PubMed ID: 35014625)
1. Targeting the undruggable oncogenic KRAS: the dawn of hope.
Asimgil H; Ertetik U; Çevik NC; Ekizce M; Doğruöz A; Gökalp M; Arık-Sever E; Istvanffy R; Friess H; Ceyhan GO; Demir IE
JCI Insight; 2022 Jan; 7(1):. PubMed ID: 35014625
[TBL] [Abstract][Full Text] [Related]
2. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract][Full Text] [Related]
3. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
4. KRAS-targeted therapies in advanced solid cancers: drug the undruggable?
Saleh K; Kordahi M; Felefly T; Kourie HR; Khalife N
Pharmacogenomics; 2021 Jul; 22(10):587-590. PubMed ID: 34148378
[No Abstract] [Full Text] [Related]
5. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
6. Targeting RAS in pediatric cancer: is it becoming a reality?
Vaseva AV; Yohe ME
Curr Opin Pediatr; 2020 Feb; 32(1):48-56. PubMed ID: 31815779
[TBL] [Abstract][Full Text] [Related]
7. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
Khan S; Budamagunta V; Zhou D
Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
[TBL] [Abstract][Full Text] [Related]
9. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
10. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.
Liu H; Qian F
Theranostics; 2022; 12(3):1321-1332. PubMed ID: 35154489
[TBL] [Abstract][Full Text] [Related]
11. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
Boumelha J; Molina-Arcas M; Downward J
Clin Cancer Res; 2023 Dec; 29(24):5012-5020. PubMed ID: 37581538
[TBL] [Abstract][Full Text] [Related]
12. CRISPR and KRAS: a match yet to be made.
Bender G; Fahrioglu Yamaci R; Taneri B
J Biomed Sci; 2021 Nov; 28(1):77. PubMed ID: 34781949
[TBL] [Abstract][Full Text] [Related]
13. Targeting Mutant KRAS for Anticancer Therapy.
Chen F; Alphonse MP; Liu Y; Liu Q
Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
[TBL] [Abstract][Full Text] [Related]
14. Targeting mutated GTPase KRAS in tumor therapies.
Fan G; Lou L; Song Z; Zhang X; Xiong XF
Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
[TBL] [Abstract][Full Text] [Related]
15. KRAS G12C inhibition and innate immune targeting.
Tani T; Kitajima S; Conway EB; Knelson EH; Barbie DA
Expert Opin Ther Targets; 2021 Mar; 25(3):167-174. PubMed ID: 33703985
[TBL] [Abstract][Full Text] [Related]
16. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
Nyíri K; Koppány G; Vértessy BG
Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
[TBL] [Abstract][Full Text] [Related]
17. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
18. Progress in targeting RAS with small molecule drugs.
McCormick F
Biochem J; 2019 Jan; 476(2):365-374. PubMed ID: 30705085
[TBL] [Abstract][Full Text] [Related]
19. Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers.
Kim J
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069255
[TBL] [Abstract][Full Text] [Related]
20. Targeting KRAS
Ciardiello D; Maiorano BA; Martinelli E
ESMO Open; 2023 Feb; 8(1):100745. PubMed ID: 36549128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]